2023 World Conference on Lung Cancer (Posters)-EP12.01. Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results

EP12.01. Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results - PDF(Slides)

Back to course

Pdf Summary

Aumolertinib, a third-generation tyrosine kinase inhibitor, has shown promise in treating non-small cell lung cancer (NSCLC) patients with EGFR co-mutations. A retrospective study was conducted with 62 advanced NSCLC patients who were given aumolertinib as their first-line therapy. The study aimed to evaluate the outcomes of aumolertinib monotherapy and combination therapy in terms of overall response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety.<br /><br />The results showed that aumolertinib monotherapy had an ORR of 66% and a DCR of 96.2%. The median PFS was 20 months. Among specific subgroups, patients with TP53 co-mutations and cell cycle co-mutations had an ORR of 69% and 70.6%, respectively. Those with PD-L1 TPS 0-1 had an ORR of 72.7%. Patients with PD-L1 TPS ≥1 had an ORR of 58.8%. Aumolertinib combination therapy demonstrated even better antitumor activity, with an ORR of 88.9% and a DCR of 100%. The PFS rate at 24 months was 56.3%.<br /><br />In terms of safety, rash and diarrhea of grades 1-2 were observed in 6.5% of patients, while grade 3 adverse events were observed in 3.2% of patients.<br /><br />Overall, aumolertinib monotherapy showed promising results in NSCLC patients with EGFR co-mutations. Aumolertinib combination therapy demonstrated even better antitumor activity. This retrospective study provides real-world evidence of the efficacy and safety of aumolertinib as a first-line therapy for NSCLC patients with EGFR co-mutations.

Asset Subtitle

Shencun Fang

Meta Tag

Speaker Shencun Fang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Aumolertinib

tyrosine kinase inhibitor

NSCLC

EGFR co-mutations

retrospective study

monotherapy

combination therapy

PFS rate

antitumor activity

safety